乳腺癌随访和药物副作用管理策略的研究进展

doi:10.11904/j.issn.1002-3070.2022.04.015

Abstract

Abstract: Breast cancer is the malignant tumor with the highest incidence in women.With the continuous improvement of diagnostic technology and treatment methods,the survival period of breast cancer patients after receiving systemic therapy has been significantly prolonged.This requires long-term follow-up for early detection of local recurrence and distant metastasis.In addition,hormone-sensitive breast cancer also needs to be given endocrine therapy for 5~10 years,and the full management of side effects also requires follow-up,improve the quality of life of patients,and provide patients with physical and psychological support.This article makes a brief review on breast cancer follow-up related aspects in recent years.

Key words: Breast cancer, Follow-up, Side effects management, Psychological support

CLC Number:

R737.9

ZHAO Danni, YAN Shi, CAI Li. Research progress on follow - up and drug side effect management strategy of breast cancer[J]. Journal of Practical Oncology, 2022, 36(4): 369-373.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.04.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I4/369

References

1 Ferlay J,Colombet M,Soerjomataram I,et al.Cancer statistics for the year 2020:An overview[J].Int J Cancer,2021,10:100.
2 Allemani C,Matsuda T,Di Carlo V,et al.Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.
3 Sopik V,Sun P,Narod SA.Predictors of time to death after distant recurrence in breast cancer patients[J].Breast Cancer Res Treat,2019,173(2):465-474.
4 马飞,徐兵河,邵志敏.乳腺癌随访及伴随疾病全方位管理指南[J].中华肿瘤杂志,2019,41(1):29-41.
5 Moy L,Bailey L,D Orsi C,et al.ACR appropriateness criteria stage I breast cancer:initial workup and surveillance for local recurrence and distant metastases in asymptomatic women[J].J Am Coll Radiol,2017,14(5):282-292.
6 Aarts A,Duffy SW,Geurts S,et al.Towards evidence-based follow-up intervals for breast cancer survivors:Estimates of the preclinical detectable phase of contralateral second breast cancer[J].Breast,2019,45:70-74.
7 Tsoutsou PG,Vozenin M,Durham A,et al.How could breast cancer molecular features contribute to locoregional treatment decision making?[J].Crit Rev Oncol Hematol,2017,110(110):43-48.
8 Sun YS,Zhao Z,Yang ZN,et al.Risk factors and preventions of breast cancer[J].Int J Biol Sci,2017,13(11):1387-1397.
9 Kozak MM,Jacobson CE,von Eyben R,et al.Patterns of distant failure by intrinsic breast cancer subtype in premenopausal women treated with neoadjuvant chemotherapy[J].Clin Breast Cancer,2018,18(5):1077-1085.
10 Yang SX,Polley EC.Systemic treatment and radiotherapy,breast cancer subtypes,and survival after long-term clinical follow-up[J].Breast Cancer Res Treat,2019,175(2):287-295.
11 Alonso-Molero J,Dierssen-Sotos T,Gomez-Acebo I,et al.Quality of life in a cohort of 1078 women diagnosed with breast cancer in spain:7-year follow-up results in the MCC-Spain Study[J].Int J Environ Res Public Health,2020,17(22):8411.
12 Hodorowicz-Zaniewska D,Herman K.Principles of follow-up assessments in patients with breast cancer after radical treatment[J].Pol Przegl Chir,2017,89(3):36-39.
13 Ignatov A,Eggemann H,Burger E,et al.Patterns of breast cancer relapse in accordance to biological subtype[J].J Cancer Res Clin Oncol,2018,144(7):1347-1355.
14 Miyashita H,Cruz C,Malamud S.Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate[J].Breast Cancer Res Treat,2020,182(2):381-388.
15 Laakmann E,Witzel I,Fasching PA,et al.Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials gepar quinto and gepar sixto[J].Breast Cancer Res,2019,21(1):60.
16 Akbari ME,Rohani-Rasaf M,Nafissi N,et al.Effecst of patho-biological factors on the survival of recurrent breast cancer cases[J].Asian Pac J Cancer Prev,2018,19(4):949-953.
17 Puvanesarajah S,Gapstur SM,Patel AV,et al.Mode of detection and breast cancer mortality by follow-up time and tumor characteristics among screened women in cancer prevention study-II[J].Breast Cancer Res Treat,2019,177(3):679-689.
18 Bychkovsky BL,Lin NU.Imaging in the evaluation and follow-up of early and advanced breast cancer:When,why,and how often?[J].Breast,2017,31(31):318-324.
19 Henry ML,Niu J,Zhang N,et al.Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients[J].JACC Cardiovasc Imaging,2018,11(8):1084-1093.
20 Jerusalem G,Lancellotti P,Kim S.HER2+ breast cancer treatment and cardiotoxicity:monitoring and management[J].Breast Cancer Res Treat,2019,177(2):237-250.
21 Rachel B,Filipa L,Keith U,et al.Management of cardiovascular disease in women with breast cancer[J].Circulation,2019,139(8):1110-1120.
22 Li J,Liu L,Feng Z,et al.Tumor markers CA15-3,CA125,CEA and breast cancer survival by molecular subtype:a cohort study[J].Breast Cancer,2020,27(4):621-630.
23 Wang W,Xu X,Tian B,et al.The diagnostic value of serum tumor markers CEA,CA19-9,CA125,CA15-3,and TPS in metastatic breast cancer[J].Clin Chim Acta,2017,470(470):51-55.
24 Waks AG,Winer EP.Breast cancer treatment:a review[J].JAMA,2019,321(3):288–300.
25 Hong J,Huang J,Shen L,et al.A prospective,randomized study of toremifene vs.tamoxifen for the treatment of premenopausal breast cancer:safety and genital symptom analysis[J].BMC Cancer,2020,16,20(1):663.
26 Vehmanen L,Sievänen H,Kellokumpu-Lehtinen P,et al.Five-year follow-up results of aerobic and impact training on bone mineral density in early breast cancer patients[J].Osteoporos Int,2021,32(3):473-482.
27 Kyriazoglou A,Zagouri F,Fotiou D,et al.Discrepancies of current recommendations in breast cancer follow-up:a systematic review[J].Breast Cancer,2019,26(5):681-686.
28 Borreani C,Alfieri S,Infante G,et al.Aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer:profiles of psychological symptoms and quality of life in different patient clusters[J].Oncology,2021,99(2):84-95.
29 Gegechkori N,Egorova N,Mhango G,et al.Bisphosphonate use and incident cardiovascular events among older breast cancer survivors[J].Breast,2019,47:28-32.
30 Cho H,Lee S,Sim SH,et al.Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients[J].Breast Cancer Res Treat,2020,182(2):333-343.
31 Kim H,Chung WB,Cho KI,et al.Diagnosis,treatment,and prevention of cardiovascular toxicity related to anti-Cancer treatment in clinical practice:an opinion paper from the working group on cardio-oncology of the Korean society of echocardiography[J].Cardiovasc Ultrasound,2018,26(1):1-25.
32 Nicolazzi MA,Carnicelli A,Fuorlo M,et al.Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer[J].Eur Rev Med Pharmacol Sci,2018,22(7):2175.
33 Li Z,Tu Y,Wu Q,et al.Clinical characteristics and outcomes of single versus double hormone receptor-positive breast cancer in 2 large databases[J].Clin Breast Cancer,2020,20(2):151-163.
34 Awan A,Esfahani K.Endocrine therapy for breast cancer in the primary care setting[J].Curr Oncol,2018,25(4):285-291.
35 Spronk I,Schellevis FG,Burgers JS,et al.Incidence of isolated local breast cancer recurrence and contralateral breast cancer:a systematic review[J].Breast,2018,39:70-79.

[1]	CHEN Jiayi, BAI Yanling. The influence of body mass index and body position fixation in breast cancer patients post-operative intensity modulated radiation therapy setup error [J]. Journal of Practical Oncology, 2022, 36(4): 327-331.
[2]	ZONG Yuxuan, PANG Da. Research progress of heat shock protein 90 in the occurrence,development and treatment of breast cancer [J]. Journal of Practical Oncology, 2022, 36(4): 381-385.
[3]	YANG Zihan, XU Shouping, PANG Da. Characteristics of breast cancer metastases to outer triangle tissue and its influencing factors [J]. Journal of Practical Oncology, 2022, 36(3): 226-232.
[4]	HE Weidan, LI Zhigao. FSIP1 promotes migration and invasion of breast cancer cells and leads to poor prognosis of patients [J]. Journal of Practical Oncology, 2022, 36(3): 233-238.
[5]	LIU Xinxin, YAO Xinhui, SUN Yuefeng, MIU Meiqi, CHEN Jing. Research progress in the role of chemokine CCL20 in breast cancer microenvironment [J]. Journal of Practical Oncology, 2022, 36(3): 250-254.
[6]	YANG Shuya, LIU Wenhui, LUO Naixiang. Research status and application prospect of UCA1 in breast cancer [J]. Journal of Practical Oncology, 2022, 36(3): 263-267.
[7]	LIU Wanying, PANG Da. Research progress on the mechanism of metastasis in invasive micropapillary carcinoma of the breast [J]. Journal of Practical Oncology, 2022, 36(3): 268-272.
[8]	SUN Yuanyuan, ZHANG Ningzhi, CAO Mengru. The mechanism and treatment progress of breast cancer lung metastasis [J]. Journal of Practical Oncology, 2022, 36(2): 173-177.
[9]	HOU Jianxun, WANG Hongbin. Research progress on the influence of exosomes in the integration of breast cancer diagnosis and treatment [J]. Journal of Practical Oncology, 2022, 36(2): 178-182.
[10]	CHEN He, WANG Qiucheng, CHENG Wen. The application progress of automatic breast ultrasound diagnosis system in breast cancer [J]. Journal of Practical Oncology, 2022, 36(2): 193-196.
[11]	ZHANG Yiyi, LI Qi, LIU Xu, WANG Yanan, ZOU Yuanjie, ZHOU Huihui, XU Chunyan, SU Shengqi, GE Xin, WANG Tong. Analysis of 5-year survival and its influencing factors of patients with cervical cancer [J]. Journal of Practical Oncology, 2022, 36(1): 7-13.
[12]	LI Weihua, ZHANG Guangfeng, MA Lili, HE Pin, WANG Wen, LI Dingfu. Construction of a breast cancer prognostic model based on metabolism-related genes in the TCGA database [J]. Journal of Practical Oncology, 2022, 36(1): 37-43.
[13]	CAO Shiyu, JIANG Yongdong. The influence of gene expression,polygene detection and biomarkers on the prognosis of Luminal A-like breast cancer [J]. Journal of Practical Oncology, 2022, 36(1): 89-93.
[14]	LUO Bo, ZHANG Qu, ZHENG Hongmei, LIANG Xinjun, ZHOU Xiaomei, WU Xinhong. Efficacy and prognosis of SRT combined with lapatinib in the treatment of HER2-positive breast cancer brain metastasis [J]. Journal of Practical Oncology, 2021, 35(6): 523-528.
[15]	SHI Runze, LI Zhigao. Research progress of precision medical strategy for different subtypes of triple negative breast cancer [J]. Journal of Practical Oncology, 2021, 35(6): 529-533.

Research progress on follow - up and drug side effect management strategy of breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments